

**Title:** Cervicovaginal and anal self-sampling for HPV testing in a transgender and gender diverse population assigned female at birth: comfort, difficulty, and willingness to use

**Authors:** Erin F Welsh<sup>1</sup>, Emily C. Andrus<sup>1</sup>, Claire B. Sandler<sup>1</sup>, Molly B. Moravek<sup>2</sup>, Daphna Stroumsa<sup>2</sup>, Shanna K. Kattari<sup>3,4</sup>, Heather M. Walline<sup>5</sup>, Christine M. Goudsmit<sup>5</sup>, Andrew F. Brouwer<sup>1,\*</sup>

**Affiliations:**

1. Department of Epidemiology, University of Michigan, Ann Arbor, MI, United States
2. Reproductive Endocrinology Clinic, Center for Reproductive Medicine, University of Michigan, Ann Arbor, MI, United States
3. School of Social Work, University of Michigan, Ann Arbor, MI, United States
4. Department of Women's and Gender Studies, University of Michigan, Ann Arbor, MI, United States
5. Department of Otolaryngology, University of Michigan, Ann Arbor, MI, United States

**Corresponding author**<sup>\*</sup>: email: [brouweaf@umich.edu](mailto:brouweaf@umich.edu); mail: Department of Epidemiology, 1415 Washington Heights, Ann Arbor, MI, 48109, United States

1 **Abstract**

2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**Background:** Transgender and gender diverse (TGD) people assigned female at birth (AFAB) face numerous barriers to preventive care, including for HPV and cervical cancer screening. Self-sampling options may expand access to HPV testing for TGD people AFAB.

**Methods:** We recruited TGD individuals AFAB to collect cervicovaginal and anal specimens at home using self-sampling for HPV testing, and individuals reported their perceptions of self-sampling. Associations between demographic and health-related characteristics and ease of use, ease of use, and willingness to use self-sampling were estimated using robust Poisson regression.

**Results:** The majority of the 101 participants who completed the study reported that the cervicovaginal self-swab was not uncomfortable (68.3%) and not difficult to use (86.1%), and nearly all (96.0%) were willing to use the swab in the future. Fewer participants found the anal swab to not be uncomfortable (47.5%), but most participants still found the anal swab to not be difficult to use (70.2%) and were willing to use the swab in the future (89.1%). Participants were more willing to use either swab if they had not seen a medical professional in the past year. About 70% of participants who reported negative experiences with either self-swab were still willing to use that swab in the future.

**Conclusions:** TGD AFAB individuals were willing to use and preferred self-sampling methods for cervicovaginal and anal HPV testing. Developing clinically approved self-sampling options for cancer screening could expand access to HPV screening for TGD AFAB populations.

**Keywords:** HPV, transgender, gender diverse, cervicovaginal, anal, oral, self-sampling

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).

29 **Introduction**

30 The human papillomavirus (HPV) is the most common STI among sexually active people, with  
31 most adults contracting at least one HPV strain during their lifetime.<sup>1</sup> HPV infections are typically  
32 asymptomatic and clear in 1–2 years, but they have the potential to contribute to future health  
33 issues such as genital warts and cancer of the cervix, anal canal, and oropharynx.

34 Approximately 22,000 instances of HPV-attributable cancer are diagnosed annually in the US  
35 among those assigned female at birth (AFAB), including 11,100 cases of cervical cancer, 4,700  
36 cases of anal cancer, and 2,300 cases of oropharyngeal cancer each year.<sup>1</sup> While the risk of

37 medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/) .

38 HPV transmission can be reduced by using protection during sexual activity, these measures do  
39 not mitigate risk completely. Additionally, while HPV vaccines are highly effective in unexposed  
40 individuals, uptake has lagged, and the vaccines are less effective in individuals who have been  
41 previously infected.<sup>2</sup> Accordingly, cervical cancer screening remains an important preventive  
42 measure.

43 Per the US Preventive Services Task Force (USPSTF), current cervical cancer screening  
44 guidelines recommend that (cisgender) women aged 21–29 years should undergo a Pap smear  
45 every three years. For women aged 30–65 years, the USPSTF suggests either continuing with a  
46 Pap smear every three years, or combining it with high-risk HPV testing, which should be  
47 conducted every five years.<sup>3</sup> Preventive cancer screening relies on regular engagement with  
48 health care practitioners and facilities. Transgender and gender diverse (TGD) individuals AFAB  
49 face many barriers to receiving preventive care, including cancer screening. (In this study, TGD  
50 includes transgender, nonbinary/gender diverse, both, or, in the case of AFAB individuals  
51 identifying as male, neither identities). TGD individuals are an especially vulnerable population,  
52 facing numerous barriers to accessing healthcare services, including discrimination, lack of  
53 provider knowledge and training, insurance exclusions, and financial barriers.<sup>4,5</sup> Many TGD  
54 individuals report delaying medical care due to fear of discrimination, providers lacking trans-  
55 specific medical care knowledge, dysphoria, and discomfort.<sup>4,5</sup> Delaying medical care places  
56 additional health risks on an already vulnerable population. Hysterectomy is rare among TGD  
57 AFAB individuals<sup>6</sup>, so cervical screening remains an important part of preventive care for this  
58 population. HPV testing and cervical cancer screening recommendations do not distinguish  
59 between cisgender (i.e., non-TGD) women and TGD individuals, despite evidence that TGD  
60 patients are substantially more likely to have inconclusive test results.<sup>7,8</sup> In addition, healthcare  
61 providers may recommend anal cancer screening using anal Pap smears or HPV testing in  
62 transmasculine individuals who engage in receptive anal sex.<sup>9</sup>

63  
64 There is limited research on the prevalence of HPV and HPV-related cancers in transmasculine  
65 individuals compared to the cisgender population.<sup>10</sup> While TGD individuals AFAB are often  
66 considered by providers and patients to be at lower risk of HPV infection because of supposedly  
67 lower rates of intercourse with partners with a penis, some studies suggest that transmasculine  
68 individuals may have a higher risk of cervical cancer and other HPV-related cancers than  
69 cisgender women due to retention of the uterine cervix, increased sexual activity, and a lack of  
70 routine cancer screenings.<sup>11,12</sup> At-home HPV testing has the potential to improve the healthcare  
71 experience of TGD individuals by providing a more private and convenient testing option and  
72 ultimately reduce healthcare disparities.<sup>13,14</sup> This study aims to bridge the gap in barriers to  
73 healthcare and HPV screening for the TGD population by assessing the feasibility of

74 administering self-collected cervicovaginal and anal swabs for HPV testing at home, as well as  
75 swab comfort, ease-of-use, and acceptability.

76

## 77 **Materials and Methods**

### 78 *Study design and population*

79 This observational study enrolled participants in 2020–21 and investigated prevalence of  
80 cervicovaginal, oral, and anal HPV among TGD people AFAB using at-home self-sampling and  
81 to assess comfort, ease-of-use, and preference for at-home cervicovaginal and anal HPV

82 medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).

83 cervicovaginal and anal specimen sampling process. The University of Michigan Institutional  
84 Review Board and the Rogel Cancer Center Protocol Review Committee approved consent  
85 documents and study protocol (HUM00166980). Ten TGD community members reviewed the  
86 study protocol, surveys, and sample collection instructions; each person was compensated with  
87 a \$100 gift card for their time.

88

89 Participants were recruited through the Michigan Medicine Comprehensive Gender Services  
90 Program, the Michigan Medicine research study recruitment website, social media posts,  
91 outreach to LGBT+ organizations, and word of mouth referrals. To qualify for the study,  
92 participants had to meet the following inclusion criteria: (1) be able and willing to provide  
93 consent, (2) be between the ages of 21–65 years of age, (3) be assigned female at birth, (4)  
94 identify as male, masculine, nonbinary, or another TGD identity, and (5) live in Michigan, Illinois,  
95 Indiana, Ohio, or Wisconsin. Individuals were excluded from participating if they: (1) had their  
96 cervix removed, or (2) self-reported being pregnant. Samples could not be collected if  
97 participants were menstruating. Participants gave written, informed consent virtually, using the  
98 SignNow platform. Participants were compensated with a \$50 gift card for full study  
99 participation.

100

### 101 *Procedures*

102 *Sample self-collection.* Individuals who consented to participate were mailed a study test kit that  
103 included materials and instructions for the collection of cervicovaginal, oral, and anal  
104 biospecimens. Participants were asked to provide an oral rinse sample using Scope brand  
105 mouthwash (Proctor & Gamble), a cervicovaginal sample using an Evelyn Brush (Rovers  
106 Medical Devices), and an anal sample using a Dacron flocked swab (Puritan Medical  
107 Products).<sup>16,17</sup> The Evelyn Brush is a cervicovaginal sampling device designed to collect cells  
108 near the cervix. The protocol for anal swab sampling was adapted from previously published  
109 protocols.<sup>18,19</sup> More details on sample collection and analysis are provided in McIntosh et al.<sup>15</sup>

110

111 *Questionnaire.* Following sample collection, participants were asked to complete two  
112 questionnaires. First, participants completed a questionnaire adapted from the validated  
113 instrument developed for the Michigan HPV and Oropharyngeal Cancer Study, consisting of  
114 questions relating to demographic information, including age, race/ethnicity, and socioeconomic  
115 status; behavior, including alcohol, tobacco, and other drug use; and sexual practices, sexual  
116 history, and sexual health care (including HPV vaccination status), testosterone status, general  
117 health, and history of STIs.<sup>19</sup> Secondly, to assess participants' individual at-home self-sampling  
118 experiences, participants answered a questionnaire was adapted from a previously developed

119 instrument, consisting of the comfort, ease-of-use, and preference for the cervicovaginal and  
120 anal self-collection procedures.<sup>20</sup> Oral sampling for HPV was not similarly assessed as it uses a  
121 non-invasive sampling method (oral rinse).

122

### 123 *Statistical analysis*

124 This study assessed three primary outcomes: perception of self-sampling swab comfortability,  
125 perception of self-sampling difficulty, and willingness to use the self-sampling method for future  
126 HPV testing. Comfort and ease-of-use were asked on a Likert scale (1-5) but analyzed as binary

127 medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint  
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  
It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/) .

128 were assessed for both the cervicovaginal and anal self-sampling experiences. Prevalence  
129 ratios and 95% confidence intervals were estimated using Poisson regression with robust error  
130 variance. All analyses were conducted using SAS 9.4. Statistical significance is reported at level  
131  $\alpha = 0.05$ .

132

## 133 **Results**

### 134 *Sample characteristics*

135 We enrolled 137 TGD participants, and 101 participants completed both the HPV self-swab  
136 collections and questionnaires. The mean age of the cohort was 28.6 years, with two-thirds of  
137 the population falling into the 21–29-year age group (Table 1). There was an even distribution of  
138 gender identity between those identifying as nonbinary, genderfluid, agender, or another gender  
139 diverse identity (48.0%) and as transgender male, transmasculine, male, or another transgender  
140 identity (49.0%). Most of the participants identified their sexual orientation as either bisexual,  
141 pansexual, or omnisexual (43.1%) or queer (36.3%). Most participants reported ever delaying  
142 medical care due to concerns relating to their gender identity (82.2%), such as expected lack of  
143 provider knowledge on transgender care, fear of discrimination, and dysphoria (Table 2). Three-  
144 quarters of participants reported having transitioned or be in the process of transitioning from  
145 their gender assigned at birth, and, of those individuals, 89.3% were currently on testosterone  
146 hormone therapy for masculinization. A small percentage reported a previous history of  
147 pregnancy (13.9%). The average BMI was 29.3, with there being an increasing distribution  
148 among individuals who are classified as normal weight (26.6%), overweight (33.0%), and obese  
149 (36.2%). Most of the population had prior experience receiving a cervical Pap test (78.2%), but  
150 few (5.9%) reported prior experience of an anal HPV test. Over half of the population reported  
151 receiving at least one dose of the HPV vaccine.

152

### 153 *Perceptions of cervicovaginal self-swab collection*

154 Overall, perceptions of the cervicovaginal self-swab collection for HPV were positive (Table 3).  
155 A large proportion of the subjects reported that using the cervicovaginal swab was not  
156 uncomfortable (68.3%), as well as not difficult to use (86.1%). Participants with a history of  
157 pregnancy were more likely to report that the swab was not uncomfortable (PR 1.31; 95% CI  
158 1.91, 1.70), and those who reported delayed medical care due to their gender identity were less  
159 likely to report the swab was not uncomfortable compared to those who never delayed medical  
160 care (PR 0.72; 95% CI 0.56, 0.92). None of the demographic or health-related variables were  
161 significantly associated with an individual's perception that the cervicovaginal swab was easy to  
162 use. Perceptions of the swab being comfortable and being easy to use were strongly correlated.

163

164 Nearly all participants expressed that they would be willing to use the cervicovaginal self-swab  
165 in the future for HPV and cervical cancer screening (96.0%). There were few significant  
166 differences in willingness to use the self-swab by any of the demographic, sexual history,  
167 medical history, or transition history characteristics, except that those who had not seen a  
168 medical professional within the past year were more willing to use the cervicovaginal self-swab  
169 than those that had (PR 1.04; 95% CI 1.00, 1.09). Willingness to use the swab was lower  
170 among those who found the swab to be uncomfortable (PR 0.71; 95% CI 0.51, 0.99). There was  
171 an overall preference for at-home self-swab collection for cervicovaginal HPV testing, with  
172 medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint  
66.3% preferring at-home testing overall, compared to 6.9% preferring in-clinic collection by a  
173 physician, 11.9% preferring a pap test in the clinic, and 12.9% with no preference.  
174

### 175 *Perceptions of anal self-swab collection*

176 Perceptions of the anal self-swab for HPV testing were less positive than those about the  
177 cervicovaginal self-swab (Table 4). Only half (47.5%) of participants reported the anal swab to  
178 not be uncomfortable, and though most still perceived the anal swab to not be difficult to use  
179 (70.2%). Participants were more likely to find the swab to be uncomfortable if they had public  
180 health insurance compared to private insurance (PR 0.51; 95% CI 0.28, 0.92), but were more  
181 likely to find the swab to not be uncomfortable if they had not seen a medical professional within  
182 the past year compared to those who had (PR 1.66; 95% CI 1.05, 2.63), had delayed medical  
183 care due to the provider lacking trans-specific knowledge compared to those that had not (PR  
184 3.00; 95% CI 1.07, 8.43), or delayed medical care due to fear of discrimination compared to  
185 those that had not (PR 2.81; 95% CI 1.09, 7.23). Participants were more likely to find the swab  
186 to be difficult to use if they were 30–39 years old compared to 21–29 years old (PR 0.66; 95%  
187 CI 0.45, 0.95), but more likely to not find the swab difficult to use if they were Asian compared to  
188 White (PR 1.43; 95% CI 1.24, 1.65), lived in a rural area compared to a suburban area (PR  
189 1.53; 95% CI 1.25, 1.88), delayed medical care because the medical professional lacked  
190 knowledge on trans-specific healthcare compared to those that did not (PR 2.00; 95% CI 1.26,  
191 1.67). Comfort and ease-of-use of the swab were again strongly correlated.

192  
193 Overall, most participants reported they would be willing to use the anal self-swab for future anal  
194 HPV testing (89.1%). Participants were more likely to be willing to use the anal swab if they  
195 were older (40–59 vs 21–29 years old: PR 1.12; 95% CI 1.03, 1.22), resided in a rural area  
196 compared to a suburban area (PR 1.19; 95% CI 1.06, 1.35), if they had not visited a medical  
197 professional in the past year (PR 1.13; 95% CI 1.05, 1.22), and they had transitioned but were  
198 not currently using hormones for masculinization. Both finding the anal swab uncomfortable (PR  
199 0.72; 95% CI 0.57, 0.91) and finding the anal swab difficult (PR 0.79; 95% CI 0.69, 0.91) were  
200 associated with decreased willingness to use the swab in the future. There was an overall  
201 preference for at-home self-swab for anal HPV testing, with 66.3% of the population preferring  
202 at home HPV testing, compared to 12.9% preferring an HPV test performed in clinic and  
203 collected by a medical professional, 7.9% preferring an anal Pap test, and 12.9% having no  
204 preference.

### 206 *Self-reported qualitative reasons for cervicovaginal and anal swab difficulty*

207 Fourteen participants (14%) reported a difficult and/or distressing experience with using the  
208 cervicovaginal swab, but ten (71%) of whom reported they would still be willing to use the

209 cervicovaginal self-swab for HPV testing in the future. Among the four participants who gave  
210 reasons for their negative experience using the cervicovaginal swab, three cited pain or  
211 discomfort when using the swab, and two cited emotional distress or dysphoria. Discomfort and  
212 emotional distress were known potential risks disclosed in the consent form, and participants  
213 were given contact information for TGD-supportive resources. Thirty participants (30%) reported  
214 a difficult or distressing experience with using the anal swab, but twenty-one (70%) reported  
215 they would still be willing to use the anal self-swab for HPV testing in the future. Seventeen  
216 participants described their negative experiences. Nine participants described difficulty with  
217 using the swab in their anus in some cases because of the size or shape of their bodies  
218 and needing partner assistance. Three participants described the experience as awkward or  
219 unfamiliar but not necessarily painful. Two reported emotional distress but noted that they  
220 appreciated the ability to do the test in the comfort of their own homes.

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint  
It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).

## 222 Discussion

223 Our analysis of the perceptions of the cervicovaginal and anal self-swab collection in a  
224 Midwestern TGD population indicated an overall broad acceptance of self-swab collection  
225 methods for HPV testing. For both the cervicovaginal and anal swabs, most participants  
226 indicated they would be willing to use these self-collection methods again in the future for HPV  
227 testing and cancer screening (96% for cervicovaginal swab, 89% for anal swab). We also found  
228 that despite difficulty or discomfort, participants reported an overall willingness to use the swabs  
229 in the future (71% and 70% of those reporting difficulty/discomfort, respectively). The preference  
230 for at-home self-swab collection for HPV testing also suggests that self-collection may be a  
231 more acceptable and accessible option for TGD individuals, who may experience discomfort or  
232 discrimination in healthcare settings. Most demographic characteristics were not significantly  
233 associated with participants' willingness to use the cervicovaginal self-swab for future  
234 cervicovaginal HPV testing. However, older and rural participants were more willing to use the  
235 anal self-swab.

236  
237 While participants overall reported a positive experience with cervicovaginal swab self-sampling,  
238 a small fraction did express some discomfort with using the swab or reported that the process  
239 generated feelings of dysphoria and emotional distress. Several participants reported that  
240 although the act of cervicovaginal self-sampling was not necessarily inherently unpleasant or  
241 painful, it was awkward and outside of their usual experiences. Increased familiarity and  
242 normalization of the procedure may improve overall acceptability and comfort. Participants  
243 reported mixed experiences with the anal self-swab in particular. Some individuals encountered  
244 difficulty with insertion, with a few noting challenges in maneuvering the swab due to their body  
245 size and shape or lack of flexibility. Others required assistance from their partner to properly use  
246 the swab. These experiences suggest that alternative instructions or guidance for diverse body  
247 types and positions may be beneficial for future self-sampling protocols. Additionally, anxiety  
248 emerged as a common theme among participants for both the cervicovaginal and anal swabs.  
249 While some individuals expressed a sense of unease or emotional distress during the self-  
250 sampling processes, they also noted a preference for experiencing these emotions in the  
251 privacy of their homes rather than in a clinical setting. This result highlights the potential benefit  
252 of self-sampling in mitigating the anxiety that some individuals may experience during in-person  
253 screening procedures.

254

255 The findings of our study align with previous research on HPV testing within the TGD  
256 population, which has highlighted the unique challenges and barriers faced by this population.<sup>5,9</sup>  
257 Most participants in our study reported delaying medical care due to concerns related to their  
258 gender identity. This result emphasizes the importance of addressing TGD-specific barriers to  
259 healthcare by improving provider knowledge in TGD healthcare and creating more inclusive and  
260 comfortable environments.<sup>22</sup> The acceptance and willingness to use self-collection methods  
261 aligns with previous research suggesting that self-sampling for HPV testing is a promising  
262 medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint  
(alternative text) TGD individuals who may experience discomfort or anxiety during traditional  
It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).  
263 clinician-collected sampling methods.<sup>23</sup> There is also growing evidence of overall acceptability of  
264 self-sampling methods for HPV testing among the cisgender female population, suggesting the  
265 potential for HPV self-sampling to increase cervical cancer screening rates when compared to  
266 the standard of care pap test.<sup>24</sup> Additionally, our findings are consistent with those reported by  
267 Maza et al., who also examined the acceptability of HPV self-sampling among transgender men  
268 in El Salvador.<sup>25</sup> Both studies highlight the potential benefits of self-sampling in addressing  
269 barriers to accessing cervical cancer screening services for TGD populations.

270

271 Our research provides healthcare professionals with a better understanding on providing  
272 medical care to the TGD population. Currently, the FDA has not approved self-collection  
273 methods for use in routine HPV screening, requiring individuals AFAB to undergo specimen  
274 collection by a physician in a medical clinic. Approval and implementation of self-collection  
275 methods for HPV testing can increase accessibility to cervical cancer screening by removing the  
276 need for a pelvic exam, which may be a barrier for some TGD individuals who experience  
277 gender dysphoria or discomfort with their genitals.<sup>26</sup> While the preference is for patients to  
278 receive in-person healthcare services with a medical professional, we acknowledge the unique  
279 barriers faced by TGD and the need for gender-affirming environments in healthcare.<sup>27</sup> We also  
280 acknowledge a profusion of internet-based services offering a variety of HPV testing; these tests  
281 are not FDA approved and are of uncertain accuracy.<sup>28</sup> It is imperative that a clinically valid, at-  
282 home tests are developed and approved.

283

284 Additionally, while the USPSTF has moved to using gender neutral language and specify  
285 anatomical features as opposed to sex, there are no transgender specific screening  
286 guidelines.<sup>4,29</sup> Lack of transgender-specific guidelines and research has been shown as a  
287 limiting factor in providing appropriate healthcare, with many providers lacking knowledge on  
288 cervical cancer risk and developing a multitude of different strategies to manage care, which  
289 may not be evidence-based or appropriate for this population; potentially leading to inadequate  
290 or inappropriate care and further contributing to disparities in healthcare.<sup>12,30</sup> The absence of  
291 clear guidelines may also affect the patient-provider relationship, with transgender individuals  
292 potentially feeling misunderstood or unsupported by healthcare providers who are not well-  
293 versed in their specific healthcare needs.<sup>30</sup> By developing transgender-specific guidelines and  
294 integrating self-sampling options, when approved, into cervical cancer screening protocols,  
295 healthcare providers can cater to the diverse needs of transgender patients, promote health  
296 equity, and ultimately improve outcomes in this underserved population.<sup>31</sup>

297



298 A strength of this study is the attention to the under-researched area of HPV and cervical cancer  
299 screening among the TGD population, including nonbinary and other gender diverse individuals  
300 specifically. By investigating multi-modal screening methods and focusing on a Midwestern  
301 cohort rather than urban, coastal areas, the study provides valuable insights into the broader  
302 TGD community's preferences and experiences with self-sampling techniques. Additionally, this  
303 study incorporated feedback from members of the TGD community who were consulted during  
304 the study design to ensure that the study materials (consent, questionnaire, sampling  
305 instructions) was comprehensive and appropriate for the population. We collected both  
306 medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint  
(quantitative and qualitative data) which allowed for a comprehensive understanding of  
It is made available under a [CC-BY-NC 4.0 International license](#).  
307 participants' preferences and potential barriers to screening, which can inform future  
308 interventions and guidelines. Our study was limited in that the population sample size was  
309 relatively small (although typical of studies in TGD populations), which may limit the  
310 generalizability of the findings to the broader TGD population. Additionally, most participants  
311 identified as White, and thus our work may not adequately reflect the experiences and concerns  
312 of TGD individuals from other racial and ethnic backgrounds.

313  
314 Our study demonstrated the overall acceptability cervicovaginal and anal self-sampling methods  
315 for HPV testing and cervical cancer screening among TGD individuals AFAB, and it lays the  
316 groundwork for future research and interventions aimed at addressing disparities in healthcare  
317 access and outcomes. Most participants reported a positive experience with the self-sampling  
318 methods, as well as an overall willingness to use these methods in the future despite any  
319 perceived difficulty or discomfort; these results may be indicative of a potential avenue to  
320 increase screening uptake and reduce barriers to healthcare in this underserved population.  
321 This study also highlights the need for tailored interventions for TGD individuals that address  
322 diverse preferences and experiences, and the need to develop evidence-based, transgender-  
323 specific guidelines for HPV testing and cervical cancer screening<sup>25,32</sup>. With continued research  
324 into the development of evidence-based and patient-centered guidelines and interventions  
325 tailored to the broader TGD population, we can work towards increasing accessibility and  
326 utilization of preventative healthcare services by TGD individuals.

## 327 **Funding**

328 This work was supported by the University of Michigan Rogel Cancer Center (NIH grant  
329 P30CA046592). Social media recruitment and data management was supported by the  
330 Michigan Institute for Clinical & Health Research (CTSA grant UL1TR002240).

331

## 332 **Acknowledgments**

333 We acknowledge our community consultants and our participants, without whom this work  
334 would not have been possible.

335

## 336 **Competing interests**

337 All authors declare that they have no competing interests.

## References

1. Cancers caused by HPV. Centers for Disease Control and Prevention. <https://www.cdc.gov/hpv/parents/cancer.html>. Published February 28, 2022. Accessed March 23, 2023.

2. Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: A review of the literature. *Human Vaccines & Immunotherapeutics*. 2018;15(1).

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.16.23284132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).

3. Cervical cancer: Screening. Recommendation: Cervical Cancer: Screening | United States Preventive Services Taskforce. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening>. Published August 21, 2018. Accessed March 23, 2023.

4. Dhillon N, Oliffe JL, Kelly MT, Krist J. Bridging barriers to cervical cancer screening in transgender men: a scoping review. *American journal of men's health*. 2020 May;14(3):1557988320925691.

5. Kattari SK, Gross EB, Harner V, et al. "Doing It On My Own Terms": Transgender and nonbinary adults' experiences with HPV self-swabbing home testing kits. *Women's Reproductive Health*. June 2022. Doi:10.1080/23293691.2022.2094737

6. James SE, Herman JL, Rankin S, Keisling M, Mottet L, Anafi M. The Report of the 2015 U.S. Transgender Survey. National Center for Transgender equality. <https://transequality.org/sites/default/files/docs/usts/USTS-Full-Report-Dec17.pdf>. Published December 2016. Accessed March 24, 2023.

7. Peitzmeier SM, Reisner SL, Harigopal P, Potter J. Female-to-male patients have high prevalence of unsatisfactory paps compared to non-transgender females: Implications for cervical cancer screening. *Journal of General Internal Medicine*. 2014;29(5):778-784. Doi:10.1007/s11606-013-2753-1

8. Gatos KC. A literature review of cervical cancer screening in transgender men. *Nursing for women's health*. 2018 Feb 1;22(1):52-62.

9. Li Y, Xu C. Human papillomavirus-related cancers. *Advances in Experimental Medicine and Biology*. 2017:23-34. Doi:10.1007/978-981-10-5765-6\_3

10. Brown B, Poteat T, Marg L, Galea JT. Human papillomavirus-related cancer surveillance, prevention, and screening among transgender men and women: Neglected populations at high risk. *LGBT Health*. 2017;4(5):315-319. Doi:10.1089/lgbt.2016.0142

11. Agénor M, Peitzmeier SM, Bernstein IM, et al. Perceptions of cervical cancer risk and screening among transmasculine individuals: Patient and provider perspectives. *Culture, Health & Sexuality*. 2016;18(10):1192-1206. Doi:10.1080/13691058.2016.1177203

12. Potter J, Peitzmeier SM, Bernstein I, et al. Cervical cancer screening for patients on the female-to-male spectrum: A narrative review and guide for Clinicians. *Journal of General Internal Medicine*. 2015;30(12). Doi:10.1007/s11606-015-3462-8

13. McRee A-L, Gower AL, Reiter PL. Preventive healthcare services use among transgender young adults. *International Journal of Transgenderism*. 2018;19(4):417-423. doi:10.1080/15532739.2018.1470593

14. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES): HPV Risk. <https://www.cdc.gov/nchs/data/nhanes/2009-2010/manuals/HPV.pdf>. Published 2009. Accessed March 24, 2023.

15. McIntosh RD, Andrus EC, Walling HM, Sandler CB, Goudsmit CM, Moravek MB, Stroumsa D, Kattari SK, Brouwer AF. Prevalence and determinants of cervicovaginal, oral, and anal HPV infection in a population of transgender and gender diverse people assigned female at birth. medRxiv.

16. Evalyn® Brush. Rovers Medical Devices. <https://www.roversmedicaldevices.com/cell-sampling-devices/evalyn-brush/>. Published October 7, 2022. Accessed April 20, 2023.

17. Nyitray AG, Carvalho da Silva RJ, Baggio ML, et al. Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: The HPV in men study. *Journal of Infectious Diseases*. 2011;204(11):1711-1722. doi:10.1093/infdis/jir637

18. Patel P, Bush T, Kojic EM, et al. Prevalence, incidence, and clearance of anal high-risk human papillomavirus infection among HIV-infected men in the sun study. *The Journal of Infectious Diseases*. 2017;217(6):953-963. doi:10.1093/infdis/jix607

19. Eisenberg MC, Campredon LP, Brouwer AF, et al. Dynamics and determinants of HPV infection: The Michigan HPV and oropharyngeal cancer (M-hoc) study. *BMJ Open*. 2018;8(10). doi:10.1136/bmjopen-2018-021618

20. Gottschlich A, Rivera-Andrade A, Grajeda E, Alvarez C, Mendoza Montano C, Meza R. Acceptability of human papillomavirus self-sampling for cervical cancer screening in an indigenous community in Guatemala. *Journal of Global Oncology*. 2017;3(5):444-454. doi:10.1200/jgo.2016.005629

21. Zhu X, MacLaughlin KL, Fan C, et al. Awareness of HPV testing and acceptability of self-sampling for cervical cancer screening among women in Minnesota. *Journal of General Internal Medicine*. 2021;37(6). doi:10.1007/s11606-021-06854-x

22. Seay J, Ranck A, Weiss R, Salgado C, Fein L, Kobetz E. Understanding transgender men's experiences with and preferences for cervical cancer screening: A rapid assessment survey. *LGBT Health*. 2017;4(4):304-309. doi:10.1089/lgbt.2016.0143

23. Reisner SL, Veters R, Leclerc M, et al. Mental health of transgender youth in care at an adolescent urban community health center: A matched retrospective cohort study. *Journal of Adolescent Health*. 2015;56(3):274-279. doi:10.1016/j.jadohealth.2014.10.264

24. Johnson AH, Hill I, Beach-Ferrara J, Rogers BA, Bradford A. Common barriers to healthcare for transgender people in the U.S. Southeast. *International Journal of Transgender Health*. 2019;21(1):70-78. doi:10.1080/15532739.2019.1700203

25. Yeh PT, Kennedy CE, de Vuyst H, Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: A systematic review and meta-analysis. *BMJ Global Health*. May 2019. doi:10.1136/bmjgh-2018-001351

26. Maza M, Meléndez M, Herrera A, et al. Cervical cancer screening with human papillomavirus self-sampling among transgender men in El Salvador. *LGBT Health*. 2020;7(4):174-181. doi:10.1089/lgbt.2019.0202

27. Connolly D, Hughes X, Berner A. Barriers and facilitators to cervical cancer screening among transgender men and non-binary people with a cervix: A systematic narrative review. *Preventive Medicine*. 2020;135. doi:10.1016/j.ypmed.2020.106071

28. Gender-affirming care for young people: A guide for healthcare providers. U.S. Department of Health and Human Services. <https://opa.hhs.gov/sites/default/files/2022-03/gender-affirming-care-young-people-march-2022.pdf>. Published 2022. Accessed March 24, 2023.

29. Underferth D. Should you get a home HPV test? MD Anderson Cancer Center. <https://www.mdanderson.org/cancerwise/should-you-get-a-home-hpv-test.h00-159463212.html>. Published August 18, 2021. Accessed April 15, 2023.

30. Caughey AB, Krist AH, Wolff TA, et al. USPSTF approach to addressing sex and gender when making recommendations for Clinical Preventive Services. *JAMA*. 2021;326(19). doi:10.1001/jama.2021.15731

31. Snelgrove JW, Jasudavicius AM, Rowe BW, Head EM, Bauer GR. “completely out-at-sea” with “Two-gender medicine”: A qualitative analysis of physician-side barriers to providing healthcare for transgender patients. *BMC Health Services Research*. 2012;12(1). doi:10.1186/1472-6963-12-110

32. Poteat T, German D, Kerrigan D. Managing uncertainty: A grounded theory of stigma in transgender health care encounters. *Social Science & Medicine*. 2013;84:22-29. doi:10.1016/j.socscimed.2013.02.019

33. Reisner SL, Poteat T, Keatley JA, et al. Global health burden and needs of transgender populations: A Review. *The Lancet*. 2016;388(10042):412-436. doi:10.1016/s0140-6736(16)00684-x

**Table 1. Demographic characteristics of participants. (N=101)**

	n	%
<u>Age Group</u>		
21-29	67	66.7
30-39	29	28.4
40-59	6	5.9
<u>Race/Ethnicity</u>		
Multiracial	8	7.9
Asian	5	4.9
Black, African American, or African	5	4.9
<u>Gender Identity</u>		
Nonbinary, genderfluid, agender	49	48.5
Transgender male / transmasculine / male	49	48.5
Other / Prefer not to label	2	3.0
<u>Sexual Orientation</u>		
Straight or heterosexual	3	2.9
Gay / Lesbian	9	8.8
Bisexual, pansexual, or omnisexual	44	43.1
Asexual or demisexual	8	7.8
Queer	37	36.3
Other / Prefer not to label	1	1.1
<u>Highest Level of Education</u>		
High school or less	8	7.8
Some college	27	26.5
2- or 4-year degree	46	45.1
Professional or doctorate degree	21	20.6
<u>Marital Status</u>		
Never married or partnered	25	11.8
Single partner, never married	12	24.5
Single partner, married	47	46.1
Multiple committed partners	11	10.9
Separated, divorced, or widowed	7	6.7
<u>Employment status</u>		
Student	22	21.6
Disabled and not working	10	9.8
Unemployed, not looking for work	5	4.9
Unemployed, looking for work	12	11.8
Part-time	15	14.7
Full-time	38	37.1
<u>Yearly household income</u>		
Less than \$10,000	17	16.8
\$10,000 - \$19,999	19	18.8

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).

\$20,000 - \$39,999	20	19.9
\$40,000 - \$49,999	21	20.8
\$50,000 +	24	23.8
<hr/>		
<u>Developed Environment</u>		
Rural	6	5.9
Suburban	49	48.0
Urban	47	46.1
<hr/>		
Public insurance	31	30.7
Private insurance	67	66.3
None/Unsure	3	3.0
<hr/>		

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](#).

**Table 2. Medical and sexual history of participants. (N=101)**

	n	%
<u>Body Mass Index (BMI), kg/m<sup>2</sup> (N=94)</u>		
Underweight (< 18.5 kg/m <sup>2</sup> )	4	4.3
Normal weight (18.5-24.9 kg/m <sup>2</sup> )	25	26.6
Overweight (25.0-29.9 kg/m <sup>2</sup> )	31	33.0
Obese (≥ 30 kg/m <sup>2</sup> )	34	36.2
<u>History of sexual activity in the past 12 months</u>		
No	8	7.9
Yes	93	82.1
<u>Number of lifetime sexual partners</u>		
< 5	34	33.7
5-10	23	22.8
> 10	44	43.6
<u>Number of sexual partners within the past 6 months (N=99)</u>		
0	19	19.2
1	60	60.6
2-4	17	17.2
5+	3	3.0
<u>History of vaginal/ front hole sex (N=97)</u>		
No	2	2.1
Yes	95	97.9
<u>History of anal sex (N=95)</u>		
No	38	40.0
Yes	57	60.0
<u>History of any STI diagnosis</u>		
No	77	76.2
Yes	24	23.8
<u>Transitioned/transitioning from gender assigned at birth</u>		
No	25	24.8
Yes	76	75.2
<u>Current hormone usage for masculinization (N=57)</u>		
No	6	10.5
Yes	51	89.5
<u>History of pregnancy</u>		
No	87	86.1
Yes	14	13.9
<u>Ever had cervical Pap test or HPV test</u>		
No	22	21.8
Yes	79	78.2
<u>Have had prior anal Pap test</u>		
No	95	94.1
Yes	6	5.9

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23281324>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).

<u>Ever delayed checkups</u>		
No	18	17.8
Yes, provider lacked knowledge on trans-specific care	6	6.0
Yes, fear of discrimination	16	15.8
Yes, to avoid dysphoria or physical discomfort	61	60.4
<u>Have received any shots of the HPV vaccine</u>		
No	43	42.6

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).



**Table 3.** Prevalence and prevalence ratios of participant perceptions that using the cervicovaginal self-swab was not uncomfortable, using the cervicovaginal self-swab was not difficult, and being willing to use the cervicovaginal self-swab again for future HPV testing for cervical cancer by participant demographics, medical characteristics, and cross comparisons to the cervicovaginal self-swab characteristics and outcomes. Prevalence ratios found to be statistically significant are bolded. n = number of individuals who responded ‘yes’ within group, N = denominator for the given category, % = prevalence of individuals who responded ‘yes’ within each group (reported as a percentage), PR = prevalence ratio of individuals who responded ‘yes’ in each group compared to the referent group, and 95% CI = 95% confidence interval for each prevalence ratio. Statistics were calculated using Poisson regression with robust error variance.

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.16.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license.

	Using the cervicovaginal self-swab was not uncomfortable				Using the cervicovaginal self-swab was not difficult				Willing to use the cervicovaginal self-swab for future HPV testing for cervical cancer			
	n / N	%	PR	95% CI	n / N	%	PR	95% CI	n / N	PR	95% CI	
<b>Overall</b>	69 / 101	68.3	-	-	87 / 101	86.1	-	-	97 / 101	-	-	
<b>Demographic characteristics</b>												
<u>Gender Identity</u>												
Nonbinary, genderfluid, agender	35 / 49	71.4	1.13	0.86, 1.49	44 / 49	89.9	1.10	0.93, 1.29	48 / 49	1.04	0.96, 1.13	
Transgender male or transmasculine	31 / 49	62.3	1.00	(Ref)	40 / 49	81.6	1.00	(Ref)	46 / 49	1.00	(Ref)	
<u>Age Group</u>												
21-29	47 / 66	71.2	1.00	(Ref)	57 / 66	86.4	1.00	(Ref)	63 / 66	1.00	(Ref)	
30-39	18 / 29	62.1	0.87	0.63, 1.20	26 / 29	89.7	1.04	0.89, 1.21	29 / 29	1.05	0.99, 1.10	
40-59	4 / 6	66.7	0.94	0.52, 1.68	4 / 6	66.7	0.77	0.43, 1.37	5 / 6	0.87	0.61, 1.25	
<u>Race/Ethnicity</u>												
White	56 / 83	67.5	1.00	(Ref)	73 / 83	87.9	1.00	(Ref)	82 / 83	1.00	(Ref)	

Multiracial / Other	5 / 7	71.4	1.06	0.65, 1.73	6 / 7	85.7	0.97	0.71, 1.33	6 / 6	85	0.87	0.64, 1.17
Asian	4 / 6	66.7	0.99	0.55, 1.77	5 / 6	83.3	0.95	0.66, 1.37	6 / 7	100	1.01	0.99, 1.04
Black, African American, or African	4 / 5	80.0	1.19	0.75, 1.88	3 / 5	60.0	0.68	0.33, 1.40	3 / 5	60	0.61	0.30, 1.24
<u>Sexual Orientation</u>												
Straight / Heterosexual	1 / 3	33.3	0.43	0.09, 2.15	2 / 3	66.7	0.71	0.32, 1.60	3 / 3	100	1.02	0.98, 1.07
Gay / Lesbian	6 / 9	66.7	0.86	0.53, 1.41	7 / 9	77.8	0.83	0.58, 1.19	7 / 9	77	0.80	0.56, 1.13
Bisexual, pansexual, or omnisexual	34 / 44	77.3	1.00	(Ref)	41 / 44	93.2	1.00	(Ref)	43 / 44	100	1.00	(Ref)
Asexual or demisexual	4 / 8	50.0	0.65	0.32, 1.32	6 / 8	75.0	0.80	0.53, 1.21	8 / 8	100	1.02	0.98, 1.07
Queer	23 / 36	63.9	0.83	0.62, 1.11	30 / 36	83.3	0.89	0.76, 1.06	35 / 36	100	0.93	0.93, 1.07
<u>Developed environment</u>												
Rural	3 / 6	50.0	0.66	0.29, 1.50	5 / 6	83.3	0.97	0.67, 1.41	6 / 6	100	1.06	0.99, 1.14
Suburban	37 / 49	75.5	1.00	(Ref)	42 / 49	85.7	1.00	(Ref)	46 / 49	100	1.00	(Ref)
Urban	29 / 46	63.0	0.83	0.64, 1.10	40 / 46	87.0	1.01	0.86, 1.19	45 / 46	100	1.04	0.96, 1.13
<u>Medical insurance</u>												
Public insurance	20 / 31	64.5	0.90	0.67, 1.22	26 / 31	83.9	0.97	0.81, 1.16	29 / 31	100	0.96	0.87, 1.07
Private insurance	48 / 67	71.6	1.00	(Ref)	58 / 67	86.6	1.00	(Ref)	65 / 67	100	1.00	(Ref)
<b>Health-related characteristics</b>												
<u>Body Mass Index (BMI), kg/m<sup>2</sup> (N=94)</u>												
Normal weight (18.5-24.9 kg/m <sup>2</sup> )	19 / 25	76.0	1.00	(Ref)	22 / 25	88.0	1.00	(Ref)	25 / 25	100	1.00	(Ref)
Overweight (25.0-29.9 kg/m <sup>2</sup> )	18 / 30	60.0	0.79	0.53, 1.15	26 / 30	86.7	0.98	0.80, 1.21	28 / 29	96	0.93	0.90, 1.04
Obese (≥ 40 kg/m <sup>2</sup> )	24 / 34	70.6	0.93	0.67, 1.30	28 / 34	82.3	0.94	0.75, 1.17	32 / 34	94	0.94	0.86, 1.03
<u>Visited a medical professional within the past year</u>												
No	5 / 8	62.5	0.91	0.52, 1.58	6 / 8	75.0	0.86	0.57, 1.29	8 / 8	100	<b>1.04</b>	<b>1.00, 1.09</b>

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Yes	64 / 93	68.8	1.00	(Ref)	81 / 93	87.1	1.00	(Ref)	89 / 93	95.5	1.00	(Ref)
<u>Number of lifetime sexual partners</u>												
< 5	20 / 34	58.8	0.83	0.59, 1.17	26 / 34	76.5	0.84	0.68, 1.04	33 / 34	97.1	1.02	0.93, 1.11
5 – 10	18 / 23	78.3	1.11	0.83, 1.48	21 / 23	91.3	1.00	0.86, 1.17	22 / 23	95.5	1.00	0.90, 1.12
> 10	31 / 44	70.4	1.00	(Ref)	40 / 44	90.9	1.00	(Ref)	42 / 44	95.5	1.00	(Ref)
<u>Number of sexual partners in past 6 months (N=99)</u>												
0	13 / 19	68.4	1.11	0.77, 1.60	15 / 19	78.9	0.93	0.72, 1.20	19 / 19	100	1.05	0.99, 1.11
1	37 / 60	61.7	1.00	(Ref)	51 / 60	85.0	1.00	(Ref)	57 / 60	95	1.00	(Ref)
2-4	14 / 17	82.3	1.33	0.99, 1.80	16 / 17	94.1	1.11	0.94, 1.30	16 / 17	99	0.99	0.87, 1.13
<u>History of vaginal/ front hole sex (N=99)</u>												
No	1 / 2	50.0	0.72	0.18, 2.90	0 / 2	0	-	-	0 / 2	0	-	-
Yes	66 / 97	69.5	1.00	(Ref)	85 / 95	89.5	1.00	(Ref)	93 / 95	99	1.00	(Ref)
<u>History of any STI diagnosis</u>												
No	54 / 77	70.1	1.00	(Ref)	67 / 77	87.0	1.00	(Ref)	75 / 77	99	1.00	(Ref)
Yes	15 / 24	62.5	0.89	0.63, 1.25	20 / 24	83.3	0.96	0.78, 1.17	22 / 24	99	0.94	0.83, 1.07
<u>Transitioned/transitioning from assigned gender at birth</u>												
No	18 / 25	72.0	1.07	0.80, 1.43	23 / 25	92.0	1.09	0.94, 1.27	24 / 25	99	1.00	0.91, 1.10
Yes	51 / 76	67.1	1.00	(Ref)	64 / 76	84.2	1.00	(Ref)	73 / 76	96	1.00	(Ref)
<u>Current hormone usage for masculinization (N=57)</u>												
No	4 / 6	66.7	1.06	0.58, 1.94	5 / 6	83.3	0.97	0.66, 1.40	6 / 6	100	1.04	0.98, 1.10
Yes	32 / 51	62.7	1.00	(Ref)	44 / 51	86.3	1.00	(Ref)	49 / 51	96	1.00	(Ref)
<u>History of pregnancy</u>												

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

No	57 / 87	65.5	1.00	(Ref)	74 / 87	85.1	1.00	(Ref)	83 / 87	95.5	1.00	(Ref)
Yes	12 / 14	85.7	<b>1.31</b>	<b>1.01, 1.70</b>	13 / 14	92.9	1.09	0.92, 1.29	14 / 14	100	1.05	1.00, 1.20
<u>Ever had cervical Pap test or HPV test</u>												
No	17 / 22	77.3	1.17	0.89, 1.55	19 / 22	86.4	1.00	0.83, 1.21	21 / 22	95.5	0.99	0.90, 1.20
Yes	52 / 79	65.8	1.00	(Ref)	68 / 79	86.1	1.00	(Ref)	76 / 79	96.6	1.00	(Ref)
<u>Ever delayed checkups</u>												
No	16 / 18	88.9	1.00	(Ref)	16 / 18	88.9	1.00	(Ref)	16 / 16	88.9	1.00	(Ref)
Yes, provider lacked knowledge on trans-specific care	5 / 6	83.3	0.94	0.63, 1.39	5 / 6	83.3	0.94	0.63, 1.39	6 / 6	83.3	1.12	0.95, 1.32
Yes, fear of discrimination	9 / 16	56.2	0.63	0.40, 1.00	14 / 16	87.5	0.98	0.77, 1.26	16 / 16	99.4	1.12	0.95, 1.32
Yes, to avoid dysphoria or physical discomfort	39 / 61	63.9	<b>0.72</b>	<b>0.56, 0.92</b>	52 / 61	85.2	0.96	0.79, 1.16	59 / 61	96.7	1.09	0.92, 1.29
<u>Have received any shots of the HPV vaccine</u>												
None	29 / 43	67.4	0.98	0.75, 1.28	35 / 43	81.4	0.91	0.77, 1.07	40 / 43	93.0	0.95	0.87, 1.03
Yes	40 / 58	69.0	1.00	(Ref)	52 / 58	89.7	1.00	(Ref)	57 / 58	98.3	1.00	(Ref)
<b>Cervicovaginal HPV self-swab characteristics</b>												
<u>Using the cervicovaginal swab was not difficult</u>												
No	2 / 14	14.3	<b>0.18</b>	<b>0.05, 0.67</b>	-	-	-	-	10 / 14	71.4	<b>0.71</b>	<b>0.51, 0.99</b>
Yes	67 / 87	77.0	1.00	(Ref)	-	-	-	-	87 / 87	100	1.00	(Ref)
<u>Using the cervicovaginal swab was not uncomfortable</u>												
No	-	-	-	-	20 / 32	62.5	<b>0.64</b>	<b>0.49, 0.84</b>	29 / 32	90.6	0.92	0.82, 1.03
Yes	-	-	-	-	67 / 69	97.1	1.00	(Ref)	68 / 69	98.6	1.00	(Ref)
<u>Preferred method of screening for cervicovaginal cancer</u>												

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](#).

HPV self-test at home	52 / 69	75.4	1.00	(Ref)	64 / 64	92.8	1.00	(Ref)	68 / 69	98.3	1.00	(Ref)
HPV test in clinic collected by medical professional	4 / 7	57.1	0.76	0.39, 1.46	6 / 7	85.7	0.92	0.68, 1.26	7 / 7	100.0	1.01	0.99, 1.04
Pap test in clinic	5 / 12	41.7	0.55	0.28, 1.09	9 / 12	75.0	0.81	0.58, 1.13	10 / 12	83.3	0.85	0.65, 1.09
No preference	8 / 13	61.5	0.82	0.52, 1.28	8 / 13	61.5	0.66	0.43, 1.02	12 / 13	92.3	0.94	0.80, 1.10

**Table 4.** Prevalence and prevalence ratios of participant perceptions that using the anal self-swab was not uncomfortable, using the anal self-swab was not difficult, and being willing to use the anal self-swab again for future HPV testing for anal cancer by participant demographics, medical characteristics, and cross comparisons to the anal self-swab characteristics and outcomes. Prevalence ratios found to be statistically significant are bolded. n = number of individuals who responded ‘yes’ within group, N = denominator within the given category, % = prevalence of individuals who responded ‘yes’ within each group (reported as a percentage), PR = prevalence ratio of individuals who responded ‘yes’ in each group compared to the referent group, and 95% CI = 95% confidence interval for each prevalence ratio. Statistics were calculated using Poisson regression with robust error variance.

	Using the anal self-swab was not uncomfortable				Using the anal self-swab was not difficult				Willing to use anal self-swab for future anal HPV testing		
	n	%	PR	95% CI	n	%	PR	95% CI	n	PR	95% CI
<b>Overall</b>	48 / 101	47.5	-	-	71 / 101	70.2	-	-	90 / 101	-	-
<b>Demographic characteristics</b>											
<u>Gender Identity</u>											
Nonbinary, genderfluid, agender	20 / 49	40.8	0.77	0.50, 1.18	33 / 49	67.3	0.94	0.72, 1.22	44 / 49	1.02	0.89, 1.18
Transgender male or transmasculine	26 / 49	53.1	1.00	(Ref)	35 / 49	71.4	1.00	(Ref)	43 / 49	1.00	(Ref)
<u>Age Group</u>											
21-29	35 / 66	53.0	1.00	(Ref)	52 / 66	78.8	1.00	(Ref)	59 / 66	1.00	(Ref)
30-39	9 / 29	31.0	0.58	0.32, 1.05	15 / 29	51.7	<b>0.66</b>	<b>0.45, 0.95</b>	25 / 29	0.96	0.81, 1.14
40-59	4 / 6	66.7	1.26	0.68, 2.31	4 / 6	66.7	0.85	0.47, 1.51	6 / 6	<b>1.12</b>	<b>1.03, 1.22</b>
<u>Race/Ethnicity</u>											
White	39 / 83	47.0	1.00	(Ref)	58 / 83	69.9	1.00	(Ref)	77 / 83	1.00	(Ref)
Multiracial	4 / 7	57.1	1.22	0.61, 2.40	4 / 7	57.1	0.82	0.42, 1.58	5 / 7	0.82	0.42, 1.58

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Asian	3 / 6	50.0	1.06	0.46, 2.45	6 / 6	100.0	<b>1.43</b>	<b>1.24, 1.65</b>	6 / 6	100.0	<b>1.43</b>	<b>1.24, 1.65</b>
Black, African American, or African	2 / 5	40.0	0.85	0.28, 2.55	3 / 5	60.0	0.86	0.41, 1.78	2 / 5	40.0	0.86	0.41, 1.78
<u>Sexual Orientation</u>												
Straight or heterosexual	2 / 3	66.7	1.83	0.75, 4.47	2 / 3	66.7	0.98	0.43, 2.23	3 / 3	100.0	<b>1.13</b>	<b>1.01, 1.25</b>
Homosexual	6 / 9	66.7	<b>1.83</b>	<b>1.00, 3.36</b>	7 / 9	77.8	1.14	0.76, 1.71	7 / 9	77.8	0.88	0.61, 1.26
Bisexual, pansexual, or omnisexual	16 / 44	36.4	1.00	(Ref)	30 / 44	68.2	1.00	(Ref)	39 / 44	88.6	1.00	(Ref)
Asexual or demisexual	4 / 8	50.0	1.37	0.62, 3.05	4 / 8	50.0	0.73	0.36, 1.51	8 / 8	100.0	<b>1.13</b>	<b>1.00, 1.26</b>
Queer	19 / 36	52.8	1.45	0.88, 4.06	27 / 36	75.0	1.10	1.20, 1.79	32 / 36	88.9	1.00	0.86, 1.17
<u>Developed environment</u>												
Rural	4 / 6	66.7	1.42	0.75, 2.69	6 / 6	100.0	<b>1.53</b>	<b>1.25, 1.88</b>	6 / 6	100.0	<b>1.19</b>	<b>1.06, 1.35</b>
Suburban	23 / 49	46.9	1.00	(Ref)	32 / 49	65.3	1.00	(Ref)	41 / 49	83.7	1.00	(Ref)
Urban	21 / 46	45.7	0.97	0.63, 1.50	33 / 46	71.7	1.20	0.84, 1.44	43 / 46	93.5	1.12	0.97, 1.29
<u>Medical insurance</u>												
Public insurance	9 / 31	29.0	<b>0.51</b>	<b>0.28, 0.92</b>	23 / 31	74.2	1.06	0.82, 1.37	26 / 31	83.9	0.92	0.78, 1.09
Private insurance	38 / 67	56.7	1.00	(Ref)	47 / 67	29.8	1.00	(Ref)	61 / 67	91.0	1.00	(Ref)
<b>Health-related characteristics</b>												
<u>Body Mass Index (BMI), kg/m<sup>2</sup> (N=100)</u>												
Normal weight (18.5-24.9 kg/m <sup>2</sup> )	12 / 25	48.0	1.00	(Ref)	18 / 25	72.0	1.00	(Ref)	21 / 25	84.0	1.00	(Ref)
Overweight (25.0-29.9 kg/m <sup>2</sup> )	14 / 30	46.7	0.97	0.54, 1.73	21 / 30	70.0	0.97	0.68, 1.38	27 / 29	93.1	1.11	0.90, 1.36
Obese (≥ 30 kg/m <sup>2</sup> )	16 / 34	47.1	0.98	0.56, 1.72	22 / 34	64.7	0.90	0.63, 1.29	31 / 34	91.2	1.09	0.88, 1.34
<u>Visited a medical professional within the past year</u>												
No	6 / 8	75.0	<b>1.66</b>	<b>1.05, 2.63</b>	5 / 8	62.5	0.88	0.51, 1.53	8 / 8	100.0	<b>1.13</b>	<b>1.05, 1.22</b>

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Yes	42 / 93	45.2	1.00	(Ref)	66 / 93	71.0	1.00	(Ref)	82 / 93	88.9	1.00	(Ref)
<u>Number of lifetime sexual partners</u>												
< 5	17 / 34	50.0	1.10	0.69, 1.75	25 / 34	73.5	0.98	0.75, 1.28	29 / 34	85.3	0.89	0.77, 1.04
5 – 10	11 / 23	47.8	1.05	0.62, 1.80	13 / 23	56.5	0.75	0.51, 1.12	19 / 23	82.6	0.86	0.71, 1.05
> 10	20 / 44	45.5	1.00	(Ref)	33 / 44	75.0	1.00	(Ref)	42 / 44	95.5	1.00	(Ref)
<u>Number of partners in past 6 months (N=99)</u>												
0	10 / 19	52.6	1.13	0.68, 1.87	12 / 19	63.2	0.86	0.59, 1.25	15 / 19	78.9	0.85	0.66, 1.08
1	28 / 60	46.7	1.00	(Ref)	44 / 60	73.3	1.00	(Ref)	56 / 60	93.3	1.00	(Ref)
2-4	8 / 17	47.1	1.01	0.57, 1.79	12 / 17	70.6	0.96	0.68, 1.36	14 / 17	82.4	0.88	0.70, 1.11
<u>History of any STI diagnosis</u>												
No	34 / 77	44.2	1.00	(Ref)	53 / 77	68.8	1.00	(Ref)	67 / 77	87.1	1.00	(Ref)
Yes	14 / 24	58.3	1.32	0.87, 2.01	18 / 24	75.0	1.09	0.83, 1.43	23 / 28	82.1	1.10	0.98, 1.24
<u>Transitioned/transitioning from assigned gender at birth</u>												
No	7 / 25	28.0	0.52	0.27, 1.01	14 / 25	56.0	0.75	0.51, 1.08	23 / 25	92.0	1.04	0.90, 1.20
Yes	41 / 76	54.0	1.00	(Ref)	57 / 76	75.0	1.00	(Ref)	67 / 76	88.2	1.00	(Ref)
<u>Current hormone usage for masculinization (N=57)</u>												
No	3 / 6	50.0	0.80	0.35, 1.82	5 / 6	83.3	1.06	0.72, 1.56	6 / 6	100.0	1.11	1.01, 1.21
Yes	32 / 51	62.8	1.00	(Ref)	40 / 51	78.4	1.00	(Ref)	46 / 51	90.2	1.00	(Ref)
<u>History of anal sex (N=95)</u>												
No	18 / 38	47.4	0.96	0.63, 1.48	26 / 38	68.4	0.97	0.74, 1.28	33 / 38	86.8	0.95	0.82, 1.10
Yes	28 / 57	49.1	1.00	(Ref)	40 / 57	70.2	1.00	(Ref)	52 / 57	91.2	1.00	(Ref)
<u>Ever had pap smear or HPV test for anal cancer</u>												
No	48 / 95	50.5	1.00	(Ref)	67 / 95	70.5	1.00	(Ref)	87 / 95	91.6	1.00	(Ref)

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.



Yes	0 / 6	0	-	-	4 / 6	66.7	0.94	0.53, 1.69	3 / 6	50.0	0.55	0.24, 1.22
<u>Ever delayed checkups</u>												
No	4 / 18	22.2	1.00	(Ref)	9 / 18	50.0	1.00	(Ref)	15 / 18	83.3	1.00	(Ref)
Yes, provider lacked knowledge on trans-specific care	4 / 6	66.7	<b>3.00</b>	<b>1.07, 8.43</b>	6 / 6	100.0	<b>2.00</b>	<b>1.26, 1.67</b>	5 / 6	83.3	1.00	0.66, 1.51
Yes, fear of discrimination	10 / 16	62.5	<b>2.81</b>	<b>1.09, 7.23</b>	13 / 16	81.2	1.62	0.97, 2.73	16 / 16	100.0	1.20	0.98, 1.47
Yes, to avoid dysphoria or physical discomfort	30 / 61	49.2	2.21	0.90, 5.45	43 / 61	70.5	1.41	0.86, 2.30	54 / 61	88.5	1.06	0.85, 1.33
<u>Have received any shots of the HPV vaccine</u>												
No	18 / 43	41.9	0.81	0.53, 1.24	26 / 43	60.5	0.78	0.59, 1.03	36 / 43	83.7	0.90	0.78, 1.04
Yes	30 / 58	51.7	1.00	(Ref)	45 / 58	77.6	1.00	(Ref)	54 / 58	93.1	1.00	(Ref)
<b>Anal HPV self-swab characteristics</b>												
<u>Using the anal swab was not difficult</u>												
No	4 / 30	13.3	<b>0.21</b>	<b>0.08, 0.54</b>	-	-	-	-	21 / 30	70.0	<b>0.72</b>	<b>0.57, 0.91</b>
Yes	44 / 71	62.0	1.00	(Ref)	-	-	-	-	69 / 71	97.2	1.00	(Ref)
<u>Using the anal swab was not uncomfortable</u>												
No	-	-	-	-	27 / 53	50.9	<b>0.55</b>	<b>0.42, 1.73</b>	42 / 53	79.2	<b>0.79</b>	<b>0.69, 0.91</b>
Yes	-	-	-	-	44 / 48	91.7	1.00	(Ref)	48 / 48	100.0	1.00	(Ref)
<u>Preferred method of screening for anal cancer</u>												
HPV self-test at home	41 / 67	61.2	1.00	(Ref)	57 / 67	85.1	1.00	(Ref)	65 / 67	97.0	1.00	(Ref)
HPV test in clinic collected by medical professional	4 / 13	30.8	0.50	0.22, 1.16	4 / 13	30.8	<b>0.36</b>	<b>0.16, 0.82</b>	10 / 13	76.9	0.79	0.59, 1.07
Pap test in clinic	2 / 8	25.0	0.41	0.12, 1.38	3 / 8	37.5	0.44	0.18, 1.08	6 / 8	75.0	0.77	0.52, 1.16
No preference	1 / 13	7.7	0.13	0.02, 0.83	7 / 13	53.8	0.63	0.38, 1.06	9 / 13	69.2	0.71	0.49, 1.03

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.15.23294132>; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](#) .